Vertex presents new data from vx-880 phase 1/2 clinical trial at the american diabetes association 82nd scientific sessions

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today provided additional data on patients dosed in part a of its phase 1/2 clinical trial of vx‑880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with t1d with impaired hypoglycemic awareness and severe hypoglycemia. as reported last month, both patients treated with half the target dose of vx-880 achieved glucose-responsive insulin production, improvem
VRTX Ratings Summary
VRTX Quant Ranking